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Background: Curcumin displays a protective role in rat models of intestinal inflammation. However, the mechanism
of how curcumin affects on intestinal inflammation is less known. The purpose of the current study is to explore the
signal pathway in which the curcumin protecting rat from intestinal inflammation.
Methods: The intestinal inflammation rat models were made by TNBS treatment. Curcumin was added to their diet
5 days before the TNBS instillation. After that, body weight change, score of macroscopic assessment of disease activity
and microscopic scoring were utilized to analyse the severity of the induced inflammation. In addition, the
level of pro-inflammatory cytokines and anti-inflammatory were detected to determine the effect of curcumin
on intestinal inflammation. The JAK/STAT pathway of pro-inflammation response was also evaluated. Finally,
the impact of curcumin on apoptosis in intestinal inflammation was assessed by TUNEL staining.
Results: Rats pretreated with curcumin significantly reversed the decrease of body weight and increase of
colon weight derived from TNBS-induced colitis. Histological improvement was observed in response to curcumin.
In addition, curcumin attenuated TNBS-induced secretion of pro-inflammatory cytokines and M1/M2 ratio, while
stimulated the secretion of anti-inflammatory cytokines. The inhibition of pro-inflammation response was mediated
by SOCS-1, which could efficiently suppress JAK/STAT pathways. Furthermore, curcumin efficiently suppressed the
TNBS-induced apoptosis, and reduced the accumulation of cytochrome C in cytosol.
Conclusion: The anti-inflammatory effect of curcumin is realized by enhancing SOCS-1 expression and
inhibiting JAK/STAT pathways. Curcumin also plays an anti-apoptotic role in TNBS-induced intestinal
inflammation. We propose that curcumin may have therapeutic implications for human intestinal
inflammation.
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Inflammatory bowel diseases (IBD), including ulcerative
colitis and Crohn’s disease, are caused by combined the
effect of associated genes with complicated environmen-
tal factors [1]. From the point of biological processes,
IBD susceptibility is derived from various physiological
changes, such as dysregulated immunoregulation, muco-
sal barrier integrity and microbial recognition, clearance
and/or homeostasis [2]. No cure can be used for IBD at
present, however, the inflammatory process involved in
IBD can be attenuated through some therapies, so as to
improve the signs and symptoms in IBD and induce
long-term remission hopefully.
Turmeric (also called Curcuma longa) is an Indian
spice and extracted from the rhizomes of the plant. For
a long history, turmeric has used as Ayurvedic medicine
and a treatment for inflammatory conditions [3]. The
main ingredient in turmeric is curcumin, also called
diferuloymethane. Previous studied have demonstrate
that curcumin, as highly pleiotropic molecule can inter-
act with an abundance of molecular targets involved in
inflammation regulation [3].
The mechanism of curcumin regulating the inflamma-
tory response is complex. Studies have shown that with
curcumin treatment, the activities of cyclooxygenase-2
(COX-2), lipoxygenase, and inducible nitric oxide syn-
thase (iNOS) enzymes decrease, the protein kinase
(MAPK) signaling is inhibited and the levels of the in-
flammatory cytokines, including tumor necrosis factor-
alpha (TNF-α), interleukin (IL) −1, −2, −6, −8, and −12,
monocyte chemoattractant protein (MCP), and migra-
tion inhibitory protein are downregulated [3, 4]. It is
well known that global transcription factor NF-kB is
response to various signaling pathways, especially the
regulation of inflammation. Curcumin is thought to
down-regulate COX-2 and iNOS expression mediated
by NF-kB, thus improving the inflammatory process
and tumorigenesis [5, 6].
Originally, Janus kinase (JAK)/signal transducers and
activators of transcription (STAT) signaling is identified
as the signaling pathway for interferons (IFNs). After-
wards, it is identified to make contributions to inflam-
mation mediated by the immune responses of a dozen of
cytokines, the actions of various growth factors and hor-
mones [7]. As suppressor of cytokine signaling, SOCS-1,
is an important negative regulators of JAK/STAT signal-
ing shown in myeloproliferative neoplasms (MPNs) and
leukemia [8]. The induction of SOCS-1 leads to sharply
downregulate JAK2/STAT signaling and the mRNA
levels of target genes which are directly regulated by
JAK2 [9, 10]. Previous work has demonstrated the in-
hibitory action of curcumin on JAK-STAT signaling con-
tributes to its anti-inflammatory activity, and curcumin
can markedly inhibit the phosphorylation of STAT1 inbrain microglia [11]. Furthermore, curcumin can also in-
crease the expression of SOCS-1 through inhibiting class
I histone deacetylases in myeloproliferative neoplasms
[12]. However, whether the effect of curcumin on anti-
inflammatory activities in TNBS-induced intestinal in-
flammation is mediated by STAT1 and SOCS-1 is less
known.
In this work, the results of our study demonstrated
that curcumin had anti-inflammatory and anti-oxidative
effects in TNBS-induced intestinal inflammation rat
models, which inhibited the inflammation in colon, and
caused an attenuated M1/M2 ratio. We also clarified
that curcumin was involved in intestinal inflammation
through elevating the expression of SOCS-1 and sup-
pressing the phosphorylation of STAT1. Furthermore,
curcumin reduced TNBS-induced apoptosis was through
the mitochondrial pathway and declined the accumula-
tion of cytochrome C in cytosol.
Methods
Animal studies
Sprague Dawley male rats (180–200 g) were maintained
in accordance with the guidelines of the Committee for
Animal Research of Nanjing University of Chinese Medi-
cine. This experiment was manipulated in line with the
Regulations for the Administration of Affairs Concern-
ing Experimental Animals. All animal experiments were
approved by Animal Ethics Committee in Nanjing uni-
versity of Chinese medicine. A total number of 78 rats
were used. For body weight and colon tissue weight
measurement, three groups (control group, TNBS group,
and curcumin + TNBS group) of 18 rats in total were
used. 60 rats were randomly allocated into ten groups.
Group 1: TNBS group, samples collected 6 h after treat-
ment; Group 2: TNBS group, samples collected 12 h
after treatment; Group 3: curcumin + TNBS group, sam-
ples collected 6 h after treatment; Group 4: curcumin +
TNBS group, samples collected 12 h after treatment;
Group 5: control group to Group 1 ~ 4; Group 6: TNBS
group, samples collected 1 day after treatment; Group 7:
TNBS group, samples collected 2 day after treatment;
Group 8: curcumin + TNBS group, samples collected
1 day after treatment; Group 9: curcumin + TNBS group,
samples collected 2 day after treatment; Group 10: con-
trol group to Group 6 ~ 9.
To estabilish the colitis rats model, 20 mg/ml 2, 4, 6-
trinitrobenzene sulfonic acid (TNBS) (Sigma-Aldrich, St.
Louis, MO, USA) was dissolved in 50 % ethano. A rub-
ber infusion tube was positioned 8 cm from the anus to
instill TNBS into the lumen of the colon. Keep the rats
vertically for at least 1 min to ensure the TNBS enter en-
tire colon. As control, the normal group also were deliv-
ered 50 % ethanol with an equal volume. One of the rats
treated with TNBS were selected and sacrificed after
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(purity, 95 %) was purchased from BDH Company in
England. For curcumin treatment groups, a concentra-
tion of 0.25 % curcumin was added to their diet at 5 days
before the TNBS instillation. After death of the animals,
the inflamed mucosa were harvest to do macroscopic
damage scores, hematoxylin and eosin (H&E) staining,
Western Blot, and qRT-PCR analysis [13, 14].
Parameters utilized to analyse the severity of the induced
inflammation
Body weight change: the weight of each animal was mea-
sured, starting on the day before TNBS treatment, and
the change in weight was calculated as a percentage, the
baseline (marked as 100 %) being taken as the weight on
the day of the TNBS challenge.
The method of macroscopic damage scores was de-
scribed previously [15]. Briefly, 1: no damage; 2: focal
hyperemia no ulcers; 3: ulceration without hyperemia or
bowel wall thickening; 4: ulceration with inflammation
at one site, but not more than two sites of ulceration
and inflammation and not more than two major sites of
ulceration and inflammation, or one site of ulceration
extending >1 cm along length of colon; 5: if damage cov-
ered >2 cm along length of colon.
The standard of microscopic scoring followed previous
method [16]. Colons were isolated and fixed with 4 %
formalin. After embedded in paraffin, 4 μm thick
sections were obtained. Following the H&E staining,
microscopic scoring was performed by two different
pathologists blinded to evaluate. This score grades the
severity of the lesion from 0 to 6 on the basis of the
extent of inflammatory infiltrate (superficial mucosal to
deeper lesions into the muscularis propria), extent of
ulceration, and the presence or absence of necrosis.
Neutrophils were numbered in more than eight high-
power fields in six rats in groups.
Immunohistochemistry
Before experiment, xylene was used to dewax paraffin-
embedded colonic tissue every 5 min for twice. After-
wards, the tissue was rehydrated in gradient concentration
of ethanol (100–70 %) every 5 min for three times. And
then it was rehydrated in PBS for 30 min. The staining kit
(Dako Real, Cat. K5001, Dako Cytomation) was used
according to manufacturer’s instructions.
The primary antibodies were used as following: anti-
CD11c (ab52632, clone EP1347y, Abcam, Cambridge,
UK), anti-CD163 (MAB1652, clone K20-T, Abnova,
Taipei City, Taiwan). The biotinylated immunoglobulins
were used as secondary antibody and stained with 3,3’-
diaminobenzidine (DAB) (Dako Cytomation) substrate
solution. The hematoxylin (Dako Cytomation) was used
to counterstain the nucleus.Myeloperoxidase activity assay
A myeloperoxidase assay kit (HK210; Hycult biotechnol-
ogy, Netherlands) was used to measure myeloperoxidase
activity. Colon tissues were thoroughly washed with cold
PBS to remove faeces and weighed in an Eppendorf
tube. The colon lysis buffer containing 200 mM NaCl,
5 mM EDTA, 10 mM Tris, 10 % glycerol, 1 mM PMSF,
1 μg/ml leupeptide, 28 μg/ml aprotinine, pH7.4 was pre-
pared and kept cool on the ice before use. Every 10 mg
of tissue added 200 μl colon lysis buffer, and homoge-
nized in tissue homogenizer at 4 °C. The supernatant
was isolated by centrifuging and detected by using a mi-
croplate reader (Biotek) in 450 nm.
Western blot
The homogenization buffer contained 20 mM MOPS,
50 mM β-glycerophosphate, 5 mM EDTA, 1 mM DTT,
1 mM sodium vanadate, 1 mM PMSF, and 50 mM NaF.
Tissue was mixed in the homogenization buffer and son-
icated on the ice. The protein concentration in the
supernatent isolated by centrifuging was determined by
the Bradford assay (Thermo). Proteins were separated
with SDS-PAGE and then transferred to PVDF mem-
branes on the ice (Bio-Rad). The membranes was incu-
bated with appropriate primary antibody overnight at 4 °
C. After three times washed, the appropriate secondary
antibody was added and incubated for 1 h at room
temperature. After three times further washing, the en-
hanced chemiluminescence detection buffer (Amer-
sham) was dripped on the membrane. Signal was
detected by Chemiluminescence Apparatus (Bio-Rad,
CA). GAPDH was used as reference. All experiments
were repeated at least three times. The following anti-
bodies were used: SOCS-1, STAT1 and p-STAT1 (Cell
Signaling Technology, Beverly, MA).
Isolation of RNA and qRT-PCR
The colon grinded with liquid nitrogen and RNA was
isolated with TRIzol (Life Technologies). The quality of
the RNA was determined on a 1 % agarose gel for 2 h at
60 V. Reverse transcription (RT) was operated with the
Super Script III First-Stand Synthesis System (Invitro-
gen). To detect the mRNA level of the target genes,
quantitative real-time PCR (qRT-PCR) was performed
using a SYBR Premix Ex TaqII (TaKaRa). The qRT-PCR
procedure was according to the manufacturer’s instruc-
tions from TaKaRa and ran with ABI PRISM7500 Fast
Real-Time PCR System. The primers of iNOS, Fizz-1,
STAT1, SOCS-1 and β-actin (control) were listed in
Table 1.
ELISA for cytokines
Supernatants of biopsy cultures were used to ELISA de-
tection after a transient centrifugation. The cytokines
Table 1 Rat primers for real-time PCR








Fig. 1 Curcumin protects colonic tissue from TNBS-induced damage.
a The weight of rats were recorded daily after TNBS treatment. The
data shown were representative. b The colons were weighed after
5-day TNBS challenge. Pretreatment with curcumin significantly
decreases the weight of colons. c After curcumin pretreatment,
the macroscopic damage was improved. *P < 0.05, **P < 0.01,
***P < 0.001
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Abingdon, UK) and IL-10 (Immunotools, Friesoythe,
Germany) were selected. Each sample was tested in
duplicate against the appropriate standard and optical
densities measured by microplate reader (BioRad, Hemel
Hempstead, UK).
Cytochrome C releasing assay
To detect mitochondria cytochrome C release, tissue
was homogenized, and supernatant cytosol fraction
separated by centrifugation. The detection method was
following the manufacturer’s instructions (Abcam,
AB65311).
TUNEL assay
TUNEL staining was performed with an Apop Tag®
Fluorescein in situ Apoptosis Detection kit (millipore)
according to the manufacturer’s instructions. Briefly, the
tissue cryosections were fixed with 1 % paraformalde-
hyde for 10 min at room temperature. Afterwards, the
sections were thoroughly rinsed with PBS. The terminal
deoxynucleotidyl transferase enzyme mixture was used
to treat sections at 37 °C for 1 h, and kept them in a hu-
midified chamber without light. Next, the sections were
incubated with the anti-digoxigenin antibody conjugated
to fluorescein for 30 min without light. At last, sections
were viewed with laser confocal microscopy.
To identify the necrosis, the method was described
previously [17]. Briefly, a concentration of 0.1 μg/ml PI
were used to treat the 10 μm sections for 10 min. The
nuclei was counterstained with DAPI.
Results
Curcumin improves macroscopic tissue damage in TNBS-
induced IBD
Body weight is an important marker for IBD in rats. The
body weight of DNB (dinitrobenzene sulfonic acid) - in-
duced IBD rats were lower than normal rats [13]. The
normal rats had a normal diet and their body weight
increased during experiments. However, TNBS caused
stagnated body weight of rats in contrast with the weight
gain in control group (Fig. 1a). Moreover, TNBS treatment
group showed significant phenotypes of colitis in rats,including bloody diarrhea, wasting conditions, and dull re-
action. We further measured the weight of colon tissue
after 5-day TNBS challenge which located 5 cm proximal
to the rectum. The weight of colon tissue gained with
TNBS treatment (Fig. 1b). However, rats pretreated with
curcumin significantly improved the decrease of body
weight and gain of colon weight associated with TNBS-
induced colitis (Fig. 1a and b). The increase weight of
colon was a consequence of apparent mucosal thickening
[18], therefore, curcumin can efficiently decrease the
thickening derived from inflammation.
Fig. 2 Histological improvement in response to curcumin in TNBS-
induced IBD. a After TNBS treatment at indicated time, colons were
isolated and harvested. With H&E staining, the histological changes
were observed. The damage including mucosal ulceration, thickened
wall, and inflammatory cells infiltration occurred in the TNBS-treated
group, however, the damage was reduced with curcumin pretreatment.
b Histological damage score were evaluated with time course.
There were 20 rats were evaluated for each score. *P < 0.05,
**P < 0.01, ***P < 0.001
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damage degree. As indicated in Fig. 1c, an increased
inflammation in response to TNBS-induced colitis for
5 days. In contrast, attenuated inflammation with curcu-
min pretreatment. Thus, from these data, it would
appear that at experimental concentrations, curcumin
can effectively attenuate the damage in TNBS-induced
colitis.
Histological improvement in response to curcumin
The colons were isolated and sectioned. After fixing,
sections were stained with H&E. The representative sec-
tions were selected and shown in Fig. 2a, as expected,
curcumin pretreatment could alleviate inflammatory
cellular infiltrate, mucosal ulceration, as well as wall
thickening which were usually observed in TNBS-
induced colitis. In addition, the effect of curcumin on
histological damage was shown in Fig. 2b, and clearly
revealed that colonic inflammation was dramatically
reduced with curcumin treatment, but remained severely
inflamed in TNBS-induced colitis 2 days postinduction
of colitis. After 4 and 8 days induction of colitis, in
curcumin + TNBS group, there appeared to be a trend
toward totally improvement as control group. Therefore,
histological analysis indicates that curcumin plays a
critical role in improving histological phenotype in
TNBS- induced colitis.
Reduced pro-inflammatory markers/cytokines and in-
creased anti-inflammatory cytokines with curcumin
pretreatment
As we known, myeloperoxidase activity is an established
marker for inflammatory cell (mainly neutrophils) infil-
tration and activity in murine models of colitis. TNBS
group showed severe neutrophils infiltration at 4 days
postinduction of colitis. In contrast, an obviously re-
duced colonic myeloperoxidase activity with curcumin
pretreatment (Fig. 3a), indicating that curcumin inhibits
inflammatory response.
Besides, we detected the level of cytokines in periph-
eral blood which are involved in pro-inflammatory and
anti-inflammatory function, including TNF-α, IFN-γ, IL-
10, IL-13, TGF-β. TNBS could induce the increase of
pro-inflammatory factors TNF-α, IFN-γ, however, there
was a significant reduction of TNF-α, IFN-γ in curcu-
min + TNBS group (Fig. 3b) in a time- dependent man-
ner. It suggests that curcumin has an inhibition effect on
inflammation. For the anti-inflammatory cytokines,
including IL-10, IL-13, TGF-β, a slight increase was
observed in TNBS-induced colitis, which was consistent
with previous work [19]. However, in curcumin + TNBS
group, the levels of IL-10, IL-13, TGF-β in peripheral
blood were significantly elevated (Fig. 3c), implying
curcumin is benefit for anti-inflammatory activity.Therefore, these results further confirm the curcumin
appears anti-inflammatory effect in TNBS-induced IBD.
Curcumin declined M1/M2 macrophage ratio in colon
M1, termed as classically activated macrophages, have
been associated with inflammatory products such as
Fig. 3 curcumin pretreatment reduced the levels of pro-inflammatory markers/ cytokines but increased the levels of anti-inflammatory cytokines.
a Curcumin pretreatment inhibited the TNBS-induced increase of MPO activity. b The levels of pro-inflammatory cytokines TNF-α and IFN-γ were
assessed by ELISA. Curcumin pretreatment inhibited the levels of TNF-α and IFN-γ. c The levels of anti-inflammatory cytokines IL-13, TGF-β and
IL-10 were assessed by ELISA. Curcumin pretreatment elevated the levels of IL-13, TGF-β and IL-10. *P < 0.05, **P < 0.01, ***P < 0.001
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By contrast, alternative activated macrophages (M2) in-
hibit the production of pro-inflammatory cytokines and
make contributions to wound healing and tissue repair,
which were associated with high arginase 1 (Arg1), Fizz-
1 expression [21]. Colon from TNBS group had an
extremely high level of iNOS, but with curcumin pre-
treatment, the increased level was inhibited. In contrast,
the level of Fizz-1 in colon in TNBS + curcumin group
was higher than in TNBS group (Fig. 4a). Analysis of the
ratio of iNOS/Fizz-1 mRNA levels can be as an indicator
of the M1/M2 activity balance [22]. As shown in Fig. 4b,
curcumin pretreatment skewed this ratio toward Fizz-1
expression, but in TNBS group, cells tended to express
more iNOS. Since iNOS and Fizz-1 are the well known
markers of M1 and M2, these results suggest curcumin
promotes the M2 macrophage polarization.
Similarly, the levels of CD11c and CD163 as an index
of M1 and M2 surface marker [23] were also observed
by immunostaining, in consistent with the level of iNOS
and Fizz-1, there were decreased infiltration of CD11c
(M1 macrophage marker) - positive cells, but the similar
infiltration of CD163 (M2 macrophage marker) - posi-
tive cells were shown in colon in TNBS + curcumin
group (Fig. 4c), compared with TNBS group. Take to-
gether, it suggests that curcumin declines M1/M2
macrophage ratio in colon, trends toward M2 macro-
phage polarization, and finally has anti-inflammation
effect in colitis.
The effect of curcumin on anti-inflammation mediated by
SOCS-1
The suppressor of cytokine signaling-1 (SOCS-1) is a
potent negative regulator of various cytokines and it hasbeen implicated in the regulation of immune responses
[24]. Previous work has demonstrated that SOCS-1 plays
an important role in preventing murine colitis by
restricting the cytokine signals [25], however, whether
the effect of curcumin on anti-inflammation in TNBS-
induced IBD is mediated by SOCS-1 has not been clari-
fied. To this end, we detected the mRNA and protein
level of SOCS-1 in colon. An efficiently stimulative effect
of curcumin was observed on SOCS-1 in a time-
dependent manner (Fig. 5a, b), suggesting SOCS-1 is
involved in the improvement of curcumin on TNBS-
induced IBD.
SOCS-1 has been identified as a negative feedback
regulator of JAK-STAT signaling [26], while IFN-γ
induces the phosphorylation of STAT1 so as to acti-
vate the signal pathway. We have validated that
curcumin can suppress the level of IFN-γ (Fig. 3b),
as expected, phosphorylation of STAT1 was indeed
decreased with curcumin pretreatment in colon,
especially after 12 h TNBS stimulation (Fig. 5c).
Furthermore, the mRNA level of STAT1 and total
STAT1 proteins were both declined with curcumin
treatment in colon (Fig. 5c and d). Taken together,
curcumin promote the SOCS-1 expression, the in-
creased SOCS-1 and decreased IFN-γ coordinately
impaire the JAK-STAT signaling.
Curcumin reduces cell apoptosis in colon
Previous study has demonstrated that curcumin can in-
duce a p53-dependent apoptosis in human carcinoma
cells [27]. To validate the positive or negtive effect of
curcumin on apoptosis in TNBS-induced IBD, TUNEL
staining was performed. When frozen sections of colons
from rat without TNBS-induced were stained by
Fig. 4 Curcumin pretreatment declined M1/M2 macrophage ratio in colon. a The mRNA levels of iNOS and Fizz-1 were detected by qRT-PCR.
iNOS and Fizz-1 are the markers of M1 and M2. b Curcumin led to the ratio of iNOS/Fizz-1 declined. c Representative images of CD11c staining
(left sections) and CD163 staining (right sections) in colonic tissue from each group. Curcumin pretreatment decreased the areas of CD11c and
CD163 staining
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cating apoptotic cells was less in normal colon. How-
ever, after TNBS treatment, large amounts of
TUNEL-positive cells were detected in the crypts and
lamina propria of colons. In addition, granulocytes in-
filtrated into lamina propria (Fig. 6a). Colons from rat
pretreatment with curcumin contained abundant
TUNEL-stained cells after 6 h induction, but at 12 h
postinduction less TUNEL-stained cells were ob-
served, suggesting curcumin can reduce cell apoptosis
in TNBS-induced IBD.
In addition, induction of apoptosis by curcumin is
through cytochrome C release and activation of caspases
in human leukemia HL-60 cells [28]. To clarify this
process also occurs in TNBS-induced colitis, the amount
of cytochrome C, a mitochondrial apoptogenic protein,
in cytosol was detected. Rats treated with TNBS ap-
peared to be cytosolic accumulation of cytochrome C,
while the release of cytochrome C was declined in colon
in curcumin-pretreated rat (Fig. 6b). These results indi-
cate the antagonistic effect of curcumin on apoptosis in
TNBS-induced colitis is through mitochondrial pathway.Discussion
In this study, we evaluated the effects of curcumin in
a TNBS-induced rats model of IBD. The results illus-
trated that curcumin could efficiently inhibit pro-
inflammatory cytokines secretion and reduce M1/M2
ratio. The anti-inflammatory effect of curcumin effect-
ively inhibited the increase in iNOS level and the
extent of infiltrating neutrophils. In addition, we vali-
dated that the inhibition of inflammatory activity was
mediated by SOCS-1 as well as suppressing the phos-
phorylation of STAT-1.
The negative regulation of SOCS-1 on JAK2/STAT
phosphorylation was mediated a lot of cytokines [9].
Previous study has demonstrated that curcumin can
effectively induce the expression of SOCS-1 through
inhibiting the activity of class I histone deacetylases
in myeloproliferative neoplasms [12]. We also clari-
fied that curcumin can induce SOCS-1 in TNBS-
induced intestinal inflammation. SOCS-1 can directly
binds JAK2 [10], and finally degrade JAK2 through
E3 ubiquition ligase ECS complex. We detected the
decreased phosphorylation of STAT-1 as expected in
Fig. 5 The effect of curcumin on anti-inflammation was mediated by SOCS-1. a The mRNA levels of SOCS-1 were detected by qRT-PCR. Curcumin
pretreatment increased the transcription of SOCS-1. b The protein levels of SOCS-1 were detected by Western Blot at 6 and 12 h postinduction.
Curcumin pretreatment increased the protein level of SOCS-1. c The total STAT1 proteins and p-STAT1 were detected by Western Blot. The level
of p-STAT1 was declined with curcumin treatment. d The mRNA levels of STAT1 were detected by qRT-PCR. Curcumin pretreatment suppressed
the transcription of STAT1
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effect of curcumin on JAK/STAT signaling is medi-
ated by SOCS-1 in TNBS-induced intestinal inflam-
mation. However, other study has shown curcumin
suppresses JAK-STAT signaling via activation of
SHP-2 in brain microglial cells [11]. Based on these
studies, the inhibition of curcumin on JAK-STAT sig-
naling maybe complex and differently regulated in
different cells. Frequent apoptosis is usually observed
in colitis which is accompanied by loss of epithelial
cells. In an experimental study of colitis in rats,
compared with the control group, caspase-3 activity
in colon was higher in TNBS treatment group [29].
The relationship between curcumin and apoptosis is
controversial. It is said that curcumin can inhibit the
apoptosis in human and rat T lymphocytes [30],
however, others have an opposite result happened in
HL60 cell lines [31] and in vivo in colon tumors
[32]. The controversy may due to the difference of
incubation periods, the curcumin concentrations,and cell lines. In our experiment, with curcumin
pretreatment, we observed a significant attenuated
apoptosis in colons, this available data indicate that
the protective effects of curcumin against TNBS- in-
duced colitis might be, at least in part, mediated by
its anti-apoptotic effects. Moreover, we confirmed
that curcumin inhibits TNBS-mediated apoptosis in
intestinal inflammation by mitochondrial cytochrome
c release.
TNF-α is an important cytokine produced mainly by
activated monocytes and macrophages. It has been
shown that curcumin can attenuate TNF-α-induced oxi-
dative stress, colitis in rats [33]. The administration of
TNF-α antibodies can effectively treat experimental rat
colitis [34, 35]. Our results also supported the idea that
curcumin causes lower serum level of TNF-α, and the
reduced colonic tissue oxidative stress. At last, we ob-
served less apoptosis with curcumin treatment.
Melatonin (5-methoxy-N-acetyltryptamine), a derivative
of the essential amino acid tryptophan, is also useful in
Fig. 6 Cell apoptosis reduced with curcumin pretreatment in TNBS-induced colitis. a Representative TUNEL stains in colon tissues obtained from
rats in each group. Curcumin pretreatment showed fewer areas of TUNEL stains compared with the only TNBS induction. b The level of cytochrome C
was detected as described in MATERIALS AND METHODS. Cytochrome C declined in curcumin-pretreated rats
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fied to have anti-inflammatory and anti-apoptotic effects
on IBD, which is the same as curcumin. Therefore, we
may propose that the substance which has anti-
inflammatory and anti-apoptotic effect may be a potential
drug to treat IBD.
Conclusions
Curcumin has an anti-inflammatory effect which is
fulfilled by enhancing SOCS-1 expression and inhibiting
JAK/STAT pathways. Curcumin also plays an anti-
apoptotic role in TNBS-induced intestinal inflammation.
Curcumin may supply potential therapeutic implications
for human intestinal inflammation.
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